Navigation Links
HIV gets a makeover

The slow pace of AIDS research can be pinned, in no small part, on something akin to the square-peg-round-hole conundrum. The HIV-1 virus won't replicate in monkey cells, so researchers use a monkey virus -- known as SIVmac, or the macaque version of simian immunodeficiency virus -- to test potential therapies and vaccines in animals. But therapies and vaccines that are effective on SIV don't necessarily translate into human success. Now, using a combination of genetic engineering and forced adaptation, researchers at Rockefeller and the Aaron Diamond AIDS Research Center have created a version of the AIDS virus that replicates vigorously in both human and monkey cells -- an advance that has the potential to revolutionize vaccine research.

In a paper published in today's issue of Science, Paul Bieniasz, associate professor and head of the Laboratory of Retrovirology, describes how he and his colleagues maneuvered around the intrinsic immunity of primate cells by replacing just a few parts of the human virus -- the ones responsible for blocking replication in monkey cells -- with components from SIV. "Overall, the virus is a mixture of engineering and forced evolution," Bieniasz says. "It sounds simple, in theory, but it took us two years to do."

Bieniasz and Theodora Hatziioannou, a research scientist in the lab and the paper's first author, had to overcome two major obstacles: the first was a protein called TRIM5 that, in monkeys, recognizes the outer shell or "capsid" of HIV-1 but not that of SIV. By swapping out the capsid region of the HIV-1 genome for that of the monkey virus, and then selectively growing the viruses that replicated most robustly, over several generations Hatziioannou created an HIV-1 mutant that could evade the monkey cells' TRIM5 recognition.

Another bit of engineering was required to get around the second obstacle: APOBEC proteins produced by a host normally cause invading viruses to mutate so much that they can' t survive, but HIV-1 uses a protein called Vif to destroy APOBEC and prevent the attack. Monkey APOBEC proteins, however, aren't susceptible to the human virus's Vif. So Hatziioannou did another swap -- the SIV Vif gene for the HIV one -- and then another round of forced adaptation to create viruses that would multiply with vigor.

The researchers dubbed their end result simian tropic HIV (stHIV): a form of HIV-1 that only differs from the original by about 10 percent, but can effectively infect primate cells and be used to test potential therapies. "If we can make this virus work in animals the way it works in tissue culture, it will likely change the way that AIDS vaccine and therapeutics research is done," Bieniasz says.
'"/>

Source:Rockefeller University


Related biology news :

1. HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs
2. Taking Aim With Nanoparticle PEBBLEs
3. Taking the piste out of Alpine vegetation
4. Taking a flying jump
5. Taking a bite out of a fellow worker helps wasps recruit new foragers
6. Taking evolutions temperature: Researchers pinpoint the energy it takes to make a species
7. Taking the wrinkles out of motoneuronal disease
8. Cancer vaccines -- Taking a jab at cancer by stimulating the immune system
9. Unprecedented water level rise in Somalia
10. Low level of extinction during ice age linked to adaptability
11. New lab technique identifies high levels of pathogens in therapy pool

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/23/2017)... Italy , May 23, 2017  Hunova, the first robotic gym ... trunk, has been officially launched in Genoa, Italy . ... Europe and the USA . The technology ... on the market by the IIT spin-off Movendo Technology thanks to a ... the Multimedia News Release, please click: ...
(Date:4/19/2017)... , April 19, 2017 ... its vendor landscape is marked by the presence of ... is however held by five major players - 3M ... these companies accounted for nearly 61% of the global ... leading companies in the global military biometrics market boast ...
(Date:4/11/2017)... Fla. , April 11, 2017 ... and secure authentication solutions, today announced that it ... Intelligence Advanced Research Projects Activity (IARPA) to develop ... Thor program. "Innovation has been a ... IARPA,s Thor program will allow us to innovate ...
Breaking Biology News(10 mins):
(Date:8/16/2017)... ... August 16, 2017 , ... Tunnell Consulting announced today that four ... ISPE Annual Meeting and Expo , to be held October 29 through November 1 ... “Driving innovation to advance patient therapies.” , The ISPE Annual Meeting and Expo will ...
(Date:8/16/2017)... ... 16, 2017 , ... Today, 3Bar Biologics Inc ., ... in funding from an impressive group of investors, including Rev1 Ventures, Maumee Ventures, ... this investment, 3Bar is broadening availability of its groundbreaking offering that uses naturally ...
(Date:8/15/2017)... 15, 2017 After spending the past two years building ... data collection, GeneFo now offers this platform to healthcare stakeholders (hospitals, ... support, adherence, and data collection vis a vis their members, under ... successful launch of this offer. ... GeneFo ...
(Date:8/15/2017)... Boston, MA (PRWEB) , ... August 15, 2017 , ... ... unmet need that has compromised these disciplines for more than half a century. ... cannot be counted. It is widely known that molecular tags developed for this ...
Breaking Biology Technology: